Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases May 8, 2026 8:30 AM EDTCompany ...

The first quarter 2026 financial results and business update will be discussed during a conference call and webcast presentation today at 2:30 PM CET/8:30 AM ET. A webcast of the live call may be ...

Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned ...

A Colombian man carried one of the most aggressive genetic mutations known to cause early-onset Alzheimer’s disease. By all ...

Novartis Pharmaceuticals Canada Inc. ("Novartis Canada") announced today that Health Canada has granted a Notice of Compliance (NOC) for Fabhalta® (iptacopan capsules) for the treatment of adult ...

Argo Biopharma begins patient dosing in phase II trials of siRNA therapy BW-40202: Shanghai, China Wednesday, April 22, 2026, 15:00 Hrs [IST] Argo Biopharmaceutical Co., Ltd. (Arg ...

Spurred by increasing public recognition of the dangers posed by police responses to mental health and substance use crises—particularly for people of color and individuals with ...

A new study conducted by researchers from the University of Potsdam and the University of Cologne has deciphered the step-by-step assembly of the eukaryotic proteasome. Eukaryotes are organisms whose ...

Rhode Island Rep. Stephen Casey introduced a House bill on Feb. 27, which was referred to the House Corporations Committee, as reported by CFO Dive. Louisiana Rep. Gerald "Beau" Beaullieu IV pre-filed ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease that is also considered an autoimmune disorder. There is no single cure for C3G, but several treatments may slow disease progression, protect ...

Complement-mediated hemolytic uremic syndrome (CM-HUS), commonly referred to as atypical HUS, is a rare thrombotic microangiopathy caused by uncontrolled activation of the alternative complement ...